Predictive and prognostic value of integrated exon-level expression to approach drug-response and resistance to EGFR-targeted treatment in non-small cell lung cancer
|
abstract
|
Activating mutations in lung cancer are targeted by a series of
molecularly targeted therapies. Patients harboring such mutations
can receive significant benefit from these therapies. However a
proportion of patients without activating mutations can benefit from
these therapies, making it urgent to identify novel biomarkers. In a
recent publication, we demonstrated the relevance of new exon-level
expression biomarkers which predict patient’s outcome
independently from patient’s mutational status. Our aim is to
investigate the genome-wide exon-level expression of a panel of
early and late lung cancer patients. In a selected population of
late stage non-squamous non-small cell lung cancer, pathways
associated the mechanisms of action of the tyrosine kinase inhibitor
erlotinib and its associated drug resistance will be investigated
and genome-wide exon-level expression intensities will be tested for
prediction of response to treatment. In early stage NSCLC patients
who have received surgical resection only, we are planning to
explore the potential prognostic role of exon-arrays, with a special
focus on metastasization / recurrence. For this purpose, the latest
whole genome exon array platform from Affymetrix® will be used.
Our population of patients will be recruited from the St. Gallen
Lung Biopsy Biobank.
|
| |
|
|
type of project
|
fundamental research
|
|
status
|
automatically closed
|
|
start of project
|
2015
|
|
end of project
|
2016
|
|
project manager
|
Florent Baty
|
additional links & downloads
